Remarkably, these two chemokines were also highlighted by a recent meta-analysis that evaluated existing biomarkers of ICB response (16), suggesting that CXCL9 and CXCL13 are indeed the strongest individual transcriptomic predictors of ICB response independent of tumor type. The gene discussed is CXCL9; the disease is neoplasm.